AN2 Therapeutics shares rise 21.05% premarket after announcing GSK collaboration and Gates funding for TB treatment development.

AN2 Therapeutics surged 21.05% in premarket trading following the announcement of a collaboration with GSK to develop boron-based LeuRS-inhibitors targeting tuberculosis, supported by a third year of funding from the Gates Foundation. The partnership leverages AN2’s proprietary boron chemistry platform, which the company highlights as a differentiated approach to drug discovery with potential applications in infectious diseases and oncology. Both the collaboration and extended funding signal progress in addressing high-unmet-need therapeutic areas, bolstering investor confidence. The news was reiterated across multiple reports, emphasizing the strategic alliance’s potential to advance TB treatments and validate AN2’s technology. The premarket rally aligns with the perceived value of the partnership and the company’s pipeline advancements, including Phase 1 trials for other indications.